Protocolo de Actuación en Mieloma múltiple - Sociedad Asturiana ...

6. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, High-dose therapy and
autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue
treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998 Nov
1;92(9):3131-6
7. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for
multiple myeloma. N Engl J Med. 2006; 354(10):1021-30.
8. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J; International Myeloma
Working Group. International Myeloma Working Group consensus approach to the treatment
of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Blood. 2011;117(23):6063-73.
9. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, GIMEMA Italian
Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with
thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after,
double autologous stem-cell transplantation in newly díagnosed multiple myeloma: a
randomised phase 3 study. Lancet. 2010;376(9758):2075-85.
10. Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M,
Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de
Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A,
Lahuerta JJ, San Miguel J, Bladé J; on behalf of the Programa para el Estudio y la Terapéutica
de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group.
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction
pretransplantation therapy in multiplemyeloma: a randomized phase 3 PETHEMA/GEM
study. Blood. 2012 ;120(8):1589-1596.
11. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Subcutaneous
versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a
randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May;12(5):431-40.
12. Sonneveld P, Schmidt-Wolf I, van der Holt B, el Jarari L, Bertsch U , Salwender H, et al.
HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin,
Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance
with Bortezomib or Thalidomide In Patients with Newly Díagnosed Multiple Myeloma (MM).
Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 40.
13. Rajkumar V, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. A Randomized
Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-
Dose Dexamethasone (Rd) in Newly Díagnosed Multiple Myeloma (E4A03): A Trial
Coordinated by the Eastern Cooperative Oncology Group. Blood (ASH Annual Meeting
Abstracts), Nov 2007; 110: 74.
14. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B,. IMWG consensus
on aintenance therapy in multiple myeloma. Blood. 2012 Jan 23. [Epub ahead of print]
PubMed PMID: 22271445
15. Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an
individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol.
2001; 113(4):1020-34.
16. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: metanálisis of 30
randomized trials among 3948 patients. Ann Oncol. 2000; 11(11):1427-36
Grupo Asturiano de Linfoma y Mieloma
37